Matches in SemOpenAlex for { <https://semopenalex.org/work/W2417049890> ?p ?o ?g. }
Showing items 1 to 53 of
53
with 100 items per page.
- W2417049890 endingPage "5" @default.
- W2417049890 startingPage "2" @default.
- W2417049890 abstract "The introduction of targeted therapies has largely modified the treatment strategies in oncology. Two targets are currently used for defining the systemic treatment of breast cancer: hormone receptors and HER2 overexpression. Trastuzumab, a monoclonal antibody, is the only registered antiHER2 treatment in Belgium. The association of trastuzumab with chemotherapy is now the recommended adjuvant treatment for early breast cancer overexpressing HER2. Other antiHER2 medications are available and some will probably be registered soon. Angiogenesis is another potential target for improving the treatment results. The CHU Liege, as a reference center for the systemic treatment of solid tumors, participates in many international trials in order to validate these new approaches. The highest quality of care is required to be in compliance with the conduct of these clinical trials. Another benefit for the patient is the easy access to last generation medical treatments, generally not accessible in our health care system in Belgium outside of clinical trials." @default.
- W2417049890 created "2016-06-24" @default.
- W2417049890 creator A5011385404 @default.
- W2417049890 creator A5061525858 @default.
- W2417049890 creator A5071242826 @default.
- W2417049890 creator A5071675004 @default.
- W2417049890 creator A5076200732 @default.
- W2417049890 creator A5087842420 @default.
- W2417049890 date "2007-01-01" @default.
- W2417049890 modified "2023-09-26" @default.
- W2417049890 title "[Targeted therapies in breast cancer: current status and perspectives]." @default.
- W2417049890 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18214352" @default.
- W2417049890 hasPublicationYear "2007" @default.
- W2417049890 type Work @default.
- W2417049890 sameAs 2417049890 @default.
- W2417049890 citedByCount "0" @default.
- W2417049890 crossrefType "journal-article" @default.
- W2417049890 hasAuthorship W2417049890A5011385404 @default.
- W2417049890 hasAuthorship W2417049890A5061525858 @default.
- W2417049890 hasAuthorship W2417049890A5071242826 @default.
- W2417049890 hasAuthorship W2417049890A5071675004 @default.
- W2417049890 hasAuthorship W2417049890A5076200732 @default.
- W2417049890 hasAuthorship W2417049890A5087842420 @default.
- W2417049890 hasConcept C121608353 @default.
- W2417049890 hasConcept C126322002 @default.
- W2417049890 hasConcept C143998085 @default.
- W2417049890 hasConcept C177713679 @default.
- W2417049890 hasConcept C185926286 @default.
- W2417049890 hasConcept C2777863537 @default.
- W2417049890 hasConcept C2779786085 @default.
- W2417049890 hasConcept C530470458 @default.
- W2417049890 hasConcept C535046627 @default.
- W2417049890 hasConcept C71924100 @default.
- W2417049890 hasConceptScore W2417049890C121608353 @default.
- W2417049890 hasConceptScore W2417049890C126322002 @default.
- W2417049890 hasConceptScore W2417049890C143998085 @default.
- W2417049890 hasConceptScore W2417049890C177713679 @default.
- W2417049890 hasConceptScore W2417049890C185926286 @default.
- W2417049890 hasConceptScore W2417049890C2777863537 @default.
- W2417049890 hasConceptScore W2417049890C2779786085 @default.
- W2417049890 hasConceptScore W2417049890C530470458 @default.
- W2417049890 hasConceptScore W2417049890C535046627 @default.
- W2417049890 hasConceptScore W2417049890C71924100 @default.
- W2417049890 hasLocation W24170498901 @default.
- W2417049890 hasLocation W24170498902 @default.
- W2417049890 hasOpenAccess W2417049890 @default.
- W2417049890 hasPrimaryLocation W24170498901 @default.
- W2417049890 isParatext "false" @default.
- W2417049890 isRetracted "false" @default.
- W2417049890 magId "2417049890" @default.
- W2417049890 workType "article" @default.